#  Antimicrobials Reporting {-}

This section focuses on the selection of appropriate antimicrobials for reporting based on the bacterial species isolated and the clinical source of the specimen. This is a critical aspect of antimicrobial susceptibility testing, as it ensures that clinicians receive relevant and actionable information for guiding antibiotic therapy

## **General Principles** {-}

*   **Relevance to Infection:** The antimicrobials reported should be those likely to be used to treat infections caused by the isolated organism in the specific body site
*   **CLSI Guidelines:** Follow CLSI guidelines for the selection of antimicrobials to be tested and reported. CLSI provides recommendations based on the spectrum of activity of the antibiotics, the prevalence of resistance, and the clinical relevance of the organism
*   **Body Site Considerations:** The choice of antimicrobials should consider the ability of the antibiotic to reach effective concentrations at the site of infection. For example, some antibiotics do not penetrate the blood-brain barrier well, making them unsuitable for treating meningitis
*   **Intrinsic Resistance:** Report antimicrobials that are known to be active against the isolated organism. Do not report antimicrobials that the organism is intrinsically resistant to
*   **Local Resistance Patterns:** Consider local resistance patterns and antibiotic stewardship guidelines when selecting antimicrobials for reporting
*   **Antimicrobial Stewardship:** The selection of antimicrobials should support antimicrobial stewardship efforts, which aim to optimize antibiotic use and minimize the development of resistance

## **Antimicrobials for Reporting by Species and Body Site** {-}

*   **Gram-Positive Cocci**
    *   ***Staphylococcus aureus***
        *   Bloodstream Infections, Pneumonia, Skin and Soft Tissue Infections:
            *   Report: Penicillin (if susceptible), oxacillin (or cefoxitin), vancomycin, linezolid, daptomycin, trimethoprim-sulfamethoxazole, clindamycin (with D-test)
            *   Consider: Ceftaroline (if oxacillin-resistant and susceptible), telavancin, dalbavancin, oritavancin, tigecycline, ceftobiprole
        *   MRSA:
            *   Report: Vancomycin, linezolid, daptomycin, trimethoprim-sulfamethoxazole, clindamycin (with D-test)
            *   Consider: Ceftaroline, telavancin, dalbavancin, oritavancin, tigecycline, ceftobiprole
        *   Methicillin-Susceptible *Staphylococcus aureus* (MSSA):
            *   Report: Penicillin, oxacillin, cefazolin, cephalexin, clindamycin (with D-test), trimethoprim-sulfamethoxazole
    *   ***Staphylococcus epidermidis* and other Coagulase-Negative Staphylococci (CoNS)***
        *   Bloodstream Infections, Infections associated with indwelling devices:
            *   Report: Oxacillin (or cefoxitin), vancomycin, linezolid, daptomycin, trimethoprim-sulfamethoxazole
        *   Consider: Gentamicin, rifampin (in combination)
    *   ***Streptococcus pneumoniae***
        *   Respiratory Tract Infections, Meningitis:
            *   Report: Penicillin (if susceptible), ceftriaxone, cefotaxime, vancomycin, levofloxacin, moxifloxacin, linezolid
        *   Consider: Telithromycin
    *   ***Streptococcus pyogenes* (Group A Streptococcus)**
        *   Skin and Soft Tissue Infections, Pharyngitis:
            *   Report: Penicillin, amoxicillin, cephalexin, clindamycin (with D-test), erythromycin, azithromycin
        *   Consider: Ceftriaxone

*   **Gram-Negative Bacilli**
    *   ***Escherichia coli***
        *   Urinary Tract Infections, Bloodstream Infections:
            *   Report: Ampicillin (if susceptible), amoxicillin-clavulanate, cefazolin, ceftriaxone, cefepime, piperacillin-tazobactam, gentamicin, amikacin, trimethoprim-sulfamethoxazole, ciprofloxacin, levofloxacin, nitrofurantoin (urine only), fosfomycin (urine only)
            *   Consider: Carbapenems, tigecycline, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol
        *   ESBL-producing:
            *   Report: Carbapenems, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol, tigecycline, fosfomycin
    *   ***Klebsiella pneumoniae***
        *   Pneumonia, Bloodstream Infections, Urinary Tract Infections:
            *   Report: Ampicillin (if susceptible), amoxicillin-clavulanate, cefazolin, ceftriaxone, cefepime, piperacillin-tazobactam, gentamicin, amikacin, trimethoprim-sulfamethoxazole, ciprofloxacin, levofloxacin
            *   Consider: Carbapenems, tigecycline, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol
        *   Carbapenem-Resistant Enterobacteriaceae (CRE):
            *   Report: Ceftazidime-avibactam, cefiderocol, tigecycline, fosfomycin, aminoglycosides (amikacin, gentamicin)
        *   ESBL-producing:
            *   Report: Carbapenems, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol, tigecycline, fosfomycin
    *   ***Proteus mirabilis***
        *   Urinary Tract Infections:
            *   Report: Ampicillin, amoxicillin-clavulanate, cefazolin, ceftriaxone, cefepime, piperacillin-tazobactam, gentamicin, amikacin, trimethoprim-sulfamethoxazole, ciprofloxacin, levofloxacin, nitrofurantoin (urine only)
    *   ***Pseudomonas aeruginosa***
        *   Pneumonia, Bloodstream Infections, Wound Infections:
            *   Report: Piperacillin-tazobactam, ceftazidime, cefepime, ceftolozane-tazobactam, imipenem-cilastatin, meropenem, gentamicin, amikacin, ciprofloxacin, levofloxacin, colistin
            *   Consider: Aztreonam, ceftazidime-avibactam, cefiderocol
    *   ***Acinetobacter baumannii***
        *   Pneumonia, Bloodstream Infections, Wound Infections:
            *   Report: Carbapenems (if susceptible), ampicillin-sulbactam, colistin, tigecycline
            *   Consider: Minocycline, cefiderocol
    *   ***Enterobacter* species (e.g., *E. cloacae*, *E. aerogenes*)**
        *   Pneumonia, Bloodstream Infections, Urinary Tract Infections:
            *   Report: Ampicillin (if susceptible), amoxicillin-clavulanate, cefazolin, ceftriaxone, cefepime, piperacillin-tazobactam, gentamicin, amikacin, trimethoprim-sulfamethoxazole, ciprofloxacin, levofloxacin
            *   Consider: Carbapenems, tigecycline, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol
        *   ESBL-producing:
            *   Report: Carbapenems, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol, tigecycline, fosfomycin
        *   Carbapenem-Resistant:
            *   Report: Ceftazidime-avibactam, cefiderocol, tigecycline, fosfomycin, aminoglycosides (amikacin, gentamicin)

*   **Anaerobes**
    *   ***Bacteroides fragilis***
        *   Intra-abdominal Infections, Wound Infections:
            *   Report: Metronidazole, carbapenems, piperacillin-tazobactam, cefoxitin, clindamycin (if susceptible)
            *   Consider: Tigecycline, ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol

*   **Other Important Species**
    *   ***Haemophilus influenzae***
        *   Respiratory Tract Infections, Meningitis:
            *   Report: Ampicillin (if susceptible), amoxicillin-clavulanate, ceftriaxone, cefotaxime, cefuroxime, azithromycin, trimethoprim-sulfamethoxazole, ciprofloxacin, levofloxacin
    *   ***Moraxella catarrhalis***
        *   Respiratory Tract Infections:
            *   Report: Penicillin (if susceptible), amoxicillin-clavulanate, ceftriaxone, cefuroxime, azithromycin, trimethoprim-sulfamethoxazole, ciprofloxacin, levofloxacin
    *   ***Neisseria gonorrhoeae***
        *   Gonorrhea:
            *   Report: Ceftriaxone, azithromycin
    *   ***Chlamydia trachomatis***
        *   Chlamydia:
            *   Report: Azithromycin, doxycycline
    *   ***Mycoplasma pneumoniae***
        *   Pneumonia:
            *   Report: Tetracyclines, macrolides, fluoroquinolones

## **Body Site-Specific Considerations** {-}

*   **Central Nervous System (CNS)**
    *   Antimicrobials must cross the blood-brain barrier
    *   Report: Ceftriaxone, cefotaxime, vancomycin, ampicillin, meropenem, piperacillin-tazobactam, linezolid (for *Staphylococcus* and *Enterococcus*), metronidazole (for anaerobes)
*   **Lower Respiratory Tract**
    *   Consider local resistance patterns and the severity of the infection
    *   Report: Beta-lactams, macrolides, fluoroquinolones, trimethoprim-sulfamethoxazole (for *Pneumocystis jirovecii*)
*   **Urinary Tract**
    *   Consider antimicrobials that achieve high concentrations in urine
    *   Report: Nitrofurantoin, fosfomycin, trimethoprim-sulfamethoxazole, fluoroquinolones, beta-lactams, aminoglycosides
*   **Bloodstream**
    *   Report: Broad-spectrum antimicrobials effective against the likely pathogens
    *   Consider: Vancomycin, linezolid, daptomycin, ceftaroline, ceftazidime-avibactam, cefiderocol, carbapenems, aminoglycosides
*   **Skin and Soft Tissue**
    *   Report: Antimicrobials effective against *Staphylococcus* and *Streptococcus*
    *   Consider: Beta-lactams, clindamycin, trimethoprim-sulfamethoxazole, tetracyclines, linezolid, daptomycin, ceftaroline

## **Reporting Practices** {-}

*   **Susceptibility Categories:** Report susceptibility categories (S, I, R) for each antimicrobial tested
*   **MICs:** Report MIC values for relevant antimicrobials, especially for serious infections and when guiding dosing decisions
*   **Comments:** Include comments when appropriate, such as:
    *   Presence of ESBL or carbapenemase
    *   Inducible clindamycin resistance
    *   Limitations of testing
    *   Recommendations for follow-up testing
*   **Alerts:** Flag critical results, such as resistance to carbapenems or vancomycin, for immediate reporting to the clinician
*   **Electronic Reporting:** Utilize electronic laboratory information systems (LIS) to facilitate rapid and accurate reporting of results

## **Key Terms** {-}

*   **Antimicrobial Susceptibility Testing:** Laboratory tests to determine the susceptibility of a bacterium to antibiotics
*   **CLSI (Clinical and Laboratory Standards Institute):** An organization that provides standardized methods and interpretive criteria for antimicrobial susceptibility testing
*   **Susceptibility Category:** A classification (S, I, R) that indicates whether an organism is likely to be inhibited by an antimicrobial
*   **MIC (Minimum Inhibitory Concentration):** The lowest concentration of an antimicrobial that inhibits bacterial growth
*   **Empiric Therapy:** Treatment initiated before the causative organism is identified and susceptibility results are available
*   **Antimicrobial Stewardship:** Efforts to optimize antibiotic use and minimize the development of resistance
*   **ESBL (Extended-Spectrum Beta-Lactamase):** A type of beta-lactamase that hydrolyzes extended-spectrum cephalosporins
*   **CRE (Carbapenem-Resistant Enterobacteriaceae):** Enterobacteriaceae that is resistant to carbapenems
*   **MRSA (Methicillin-Resistant *Staphylococcus aureus*):** *Staphylococcus aureus* that is resistant to methicillin and other beta-lactam antibiotics
*   **VRE (Vancomycin-Resistant *Enterococcus*):** *Enterococcus* species that is resistant to vancomycin
*   **Intrinsic Resistance:** Natural resistance of a bacterial species to an antibiotic
